Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“A few years ago, we studied Lp(a) levels in more than 48,000 people in 48 countries around the world, all of whom had ASCVD, but only 13.9% actually had prior measurements of Lp(a). So, we have a real education problem for both physicians and patients, and we will not know who to treat when these new drugs become available unless we begin to test more patients for the disorder.”
Randomized trial demonstrates olpasiran significantly lowers lipoprotein(a) in atherosclerotic cardiovascular disease, suggesting potential value for targeted cardiovascular risk reduction.
Olpasiran therapy significantly reduced lipoprotein(a) concentrations in patients with established atherosclerotic cardiovascular disease. Longer and larger trials will be necessary to determine the effect of olpasiran therapy on cardiovascular disease. (Funded by Amgen; OCEAN[a]-DOSE ClinicalTrials.gov number, NCT04270760.).
No takes yet. Share an insight, caveat, or question.
O’Donoghue et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: